Welcome to

SRI Ventures

Health | Defence | Space | Energy

Creator of over $1 billion in total economic value from zero.
Founder of the first and only AI company to achieve Care Quality Commission (CQC) registration and the first deployment of autonomous clinical AI diagnosis in live clinical setting
Winner of the Prix Galien International 2024, the highest accolade in life sciences, often cited as the "Nobel Prize for Innovators".

A Founding Member of the

About Us

SRI (Simon Rasalingham Industry) Ventures builds award-winning AI and Quantum technologies fused with Biotechnology with the greatest potential impact on global human health to save lives.

Unrivaled Impact: Over $1 billion in economic value created from zero across healthcare technology ventures founded by Simon Rasalingham.
Market-Leading Exits: This includes the founding and scaling of MEDICA GROUP plc (LSE listed; exited at £269m/$339m) and Synbiotix (acquired for £50m/$63m).
Pioneering Autonomous AI: Developed Behold.ai's red dot® algorithm, the world’s first autonomous AI integrated in a live clinical setting and the first AI provider to be CQC registered.

Strategic Specializations & R&D

We fuse Autonomous AI/ML, Quantum Computing, and Biotechnology to address the most critical challenges in Health, Defence, Space, and Energy. Our multidisciplinary programs span:

Precision Oncology AI
Defence: Founding member of the GRAIL ALLIANCE
Global Regulation: Developing international healthcare technology regulatory frameworks based on standards pioneered in the UK

Scientific & Peer-Reviewed Verification

Published Research: 7 peer-reviewed publications with over 100 citations in medical AI.
Core Research: Validation of AI for rule-out of normal chest X-rays and acute triage of CT head scans.
Regulatory Firsts: First autonomous AI to rule out normal chest X-rays to receive MHRA approval integrated with CQC in live NHS settings and international setting during COVID-19 with Apollo Hospitals.
Clinical Gold Standards: One of the first FDA 510(k) clearances for triaging life-critical findings and ISO 13485 QMS Certification.

The Economic Impact Dashboard

Direct Exit Value: $402M (£319m)

This represents the combined enterprise value at the time of exit for MEDICA GROUP (LSE listed) and Synbiotix (trade sale).
NHS Productivity: $100M–$150M

Estimated value generated through the reduction in radiology reporting backlogs, improved diagnostic turnaround times, and general cost avoidance for NHS Trust clients.
Tax Contribution: $50M–$80M

Total corporation tax, VAT, business rates, and capital gains tax generated throughout the operating lifecycles of the companies.
Total Economic Value: Over $1 Billion

A comprehensive figure derived using a conservative 2.5x multiplier applied to direct exit values, consistent with HM Treasury Green Book and UKRI impact assessment frameworks and exclude SRI Ventures pipeline.

Economic Multiplier Rationale

Economic impact assessments for high-growth technology companies operating within the public sector routinely apply multiplier effects of 2.5x to 3.5x on direct enterprise value. This is consistent with methodologies endorsed by HM Treasury Green Book guidance and widely used by UK Research and Innovation (UKRI), Innovate UK, and regional development agencies.Applying a conservative 2.5x multiplier to the combined direct exit value of $402 million yields approximately $1.0 billion. When the additional quantifiable impact categories above are factored in, the $1 billion figure represents a defensible and conservative estimate of total economic value generated for the UK economy.

The late Elie Wiesel, Honoring Founding President, The Galien Foundation, Peace Nobel Laureate, University Professor and Professor of Philosophy and Religion, Boston University

“Thanks to their gifts to society and their determination to alleviate and cure its woes, these scientists deserve to be ranked among the true friends of the human race.”

Our Mission

At SRI Ventures, we build award-winning AI and Quantum technologies fused with Biotechnology to deliver solutions with the greatest potential to save human lives. Our multidisciplinary portfolio spans precision oncology radiomics, defence medical AI, and predictive medical military AI.

Founded by Simon Rasalingham, a serial entrepreneur with 25+ years of experience in scaling transformative healthcare technology. Recognised with the Prix Galien International 2024 ("The Nobel Prize for Life Sciences") and the highest accolade for Life Sciences, our founder's ventures have generated over $1 billion in total economic value for the United Kingdom